Hypoxia and photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4630-4638

  Busch, Theresa M ^a,b   Hahn, Stephen M ^a   Wileyto, E Paul ^a   Koch, Cameron J ^a   Fraker, Douglas L ^a   Zhang, Paul ^a   Putt, Mary ^a   Gleason, Kristen ^a   Shin, Daniel B ^a   Emanuele, Michael J ^a   Jenkins, Kevin ^a   Glatstein, Eli ^a   Evans, Sydney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b B13 Anatomy Chemistry Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; PHOTOFRIN; PHOTOSENSITIZING AGENT;

APPENDIX CARCINOMA; ARTICLE; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG TUMOR LEVEL; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SARCOMA; SMALL INTESTINE CARCINOMA; TISSUE OXYGENATION; TUMOR BIOPSY; TUMOR VOLUME;

APPENDICEAL NEOPLASMS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CARBOCYANINES; COLONIC NEOPLASMS; DIHEMATOPORPHYRIN ETHER; ETANIDAZOLE; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYDROCARBONS, FLUORINATED; INTESTINE, SMALL; MALE; MICROSCOPY, FLUORESCENCE; OVARIAN NEOPLASMS; OXYGEN; PHOTOCHEMOTHERAPY; SARCOMA;

EID: 3242687853     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0359     Document Type: Article

References (35)

1. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer (Phila) 2000;88:358-63.
2. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
3. Cintron JR, Pearl RK. Colorectal cancer and peritoneal carcinomatosis. Semin Surg Oncol 1996;12:267-78.
4. Pilati P, Rossi CR, Mocellin S, et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 2001;27:125-34.
5. Hendren SK, Hahn SM, Spitz FR, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 2001;8:65-71.
6. DeLaney TF, Sindelar WF, Tochner Z, et al. Phase 1 study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993;25:445-57.
7. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
8. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
9. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
10. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
11. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998;77:1386-94.
12. Foster TH, Hartley DF, Nichols MG, Hilf R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res 1993;53:1249-54.
13. Henderson BW, Fingar VH. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem Photobiol 1989;49:299-304.
14. Henderson BW, Busch TM, Vaughan LA, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000;60:525-9.
15. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996;56;405-11.
16. Evans SM, Hahn SM, Magarelli DP, et al. Hypoxia in human intraperitoneal and extremity sarcomas. Int J Radiat Oncol Biol Phys 2001;49:587-96.
17. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000;60:2018-24.
18. Ziemer LS, Koch CJ, Maity A, et al. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 2001;3:500-8.
19. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1-16.
20. Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92.
21. Laughlin KM, Evans SM, Jenkins WT, et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 1996;277:1049-57.
22. Koch CJ, Hahn SM, Rockwell KJ, et al. Pharmacokinetics of the 2-nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl)acetamide] in human patients: implications for hypoxia measurements in vivo. Cancer Chemother Pharmacol 2001;48:177-87.
23. Bellnier DA, Greco WR, Parsons JC, et al. An assay for the quantitation of Photofrin in tissues and fluids. Photochem Photobiol 1997;66:237-44.
24. Pinheiro J, Bates DM. Mixed-effects models in S and Splus. New York: Springer; 2003.
25. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimiddazole EF5. In: Sen C, Packer L, editors. Methods in enzymology: antioxidants and redox cycling, vol. 352. San Diego, CA: Academic Press, 2002. p. 3-31.
26. Lartigau E, Lusinchi A, Eschwege F, Guichard M. Tumor oxygenation: the Institut Gustave Roussy experience. In: Vaupel P, Kelleher DK, editors. Tumor hypoxia pathophysiology, clinical significance and therapeutic perspectives. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH; 1999. p. 47-52.
27. Vaupel P, Hockel M. Oxygenation status of breast cancer: the Mainz experience. In: Vaupel P, Kelleher DK, editors. Tumor hypoxia pathophysiology, clinical significance and therapeutic perspectives, Stuttgart, Germany. Wissenschaftliche Verlagsgesellschaft mbH; 1999. p. 1-11.
28. Nordsmark M, Overgaard J. Oxygenation of human tumors: the Aarhus experience. In: Vaupel P, Kelleher DK, editors. Tumor hypoxia pathophysiology, clinical significance and therapeutic perspectives Stuttgart, Germany. Wissenschaftliche Verlagsgesellschaft mbH; 1999. p. 19-27.
29. Menon C, Kutney SN, Lehr SC, et al. Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy. Clin Cancer Res 2001;7:3904-11.
30. Busch TM, Wileyto EP, Emanuele MJ, et al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res 2002;62:7273-9.
31. Khan S, Cleveland RP, Koch CJ, Schelling JR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Investig 1999;79:1089-99.
32. Bergeron M, Evans SM, Sharp FR, et al. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia. Neuroscience 1999;89:1357-66.
33. Evans SM, Laughlin KM, Pugh CR, Sehgal CM, Saunders HM. Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia. Br J Cancer 1997;76:1308-14.
34. Bialik S, Geenen DL, Sasson IE, et al. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Investig 1997;100:1363-72.
35. Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal construction, hypoxia, and gestation. Pediatr Res 1999;45:19-29.